Association between atopic dermatitis and squamous cell carcinoma: a case–control study

Cho, Janice M.; Davis, Dawn M.; Wetter, David A.; Bartley, Adam C.; Brewer, Jerry D.

doi:10.1111/ijd.13857

Cited by 20 publications

(30 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most common serious TEAEs included squamous cell carcinoma of the skin. Of note, an increased incidence of non-melanoma skin cancers in patients with AD has been reported in the literature [24][25][26]. [14,19] (N = 7); NCT01859988 [20] (N = 296); NCT01385657 [14,19] (N = 12); NCT01548404 [14] (N = 51); NCT01639040 [14] (N = 17); NCT02260986 [10] (N = 581); NCT01979016 [18] (N = 44); NCT02210780 [15] (N = 168); NCT02277743 [12] (N = 353); NCT02407756 [16] (N = 5); NCT02395133 [22] (N = 415); NCT02277769 [12] (N = 402); NCT02755649 [11] (N = 313); NCT02647086 [17] (N = 13) b These patients completed the treatment and end-of-study periods c Includes reasons of relocation, desire for pregnancy, did not want to discontinue treatment for 12 weeks, work/school conflict, and personal reasons not specified d Includes patients withdrawn from the study, both those receiving treatment at the time of withdrawal and those not receiving treatment during the safety follow-up period e Includes the following dupilumab doses in the parent study: 75 mg qw, 100 mg q4w, 150 mg qw, 200 mg q2w, 200 mg qw, 300 mg q8w, 300 mg q4w, 2 mg/kg, 4 mg/kg f These patients had screen failed in the parent study because the enrollment target was met, but they were permitted to enter the OLE Dupilumab showed substantial and sustained improvement in AD signs and symptoms from the baseline of the parent study, with continued incremental improvement beyond 52 weeks of treatment.…”

Section: Discussionmentioning

confidence: 99%

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

et al. 2020

View full text Add to dashboard Cite

Background Management of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment. Objective The aim of this study was to report the safety and efficacy of dupilumab treatment for up to 3 years in adults with moderate-to-severe AD. Methods This ongoing, multicenter, open-label extension study (LIBERTY AD OLE; NCT01949311) assessed dupilumab treatment in adults previously enrolled in dupilumab trials. Patients received dupilumab 300 mg weekly up to 148 weeks. The primary outcome was safety. Results Of 2677 patients enrolled and treated, 347 reached week 148. Mean self-reported drug compliance was 98.2%. Safety data were consistent with previously reported trials (270.1 adverse events [AEs]/100 patient-years; 6.9 serious AEs/100 patient-years) and the known dupilumab safety profile. Common AEs (≥ 5% of patients) included nasopharyngitis, AD, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reactions. AD signs and symptoms showed sustained improvements during treatment with mean (standard deviation, mean percentage change from parent study baseline) Eczema Area and Severity Index 1.4 (3.2, − 95.4%) and weekly Pruritus Numerical Rating Scale 2.2 (1.8, − 65.4%) at week 148. Limitations No control arm; fewer patients at later time points; regimen different from the approved 300 mg every 2 weeks dose. Conclusion These safety and efficacy results support dupilumab as a continuous long-term treatment for adults with moderate-to-severe AD. Trial Registration ClinicalTrials.gov: NCT01949311. Video abstract Electronic supplementary material The online version of this article (10.1007/s40257-020-00527-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Many known inflammatory and pre-neoplastic disorders are associated with impaired barrier function. [11–18] These include psoriasis, atopic dermatitis and actinic keratosis, the most common precursor to cutaneous squamous cell carcinoma [19,20]. Emollients are employed in the treatment of inflammatory disorders, and application of sunscreen has been shown to cause regression of actinic keratosis [21].…”

Section: Introductionmentioning

confidence: 99%

Selenium unmasks protective iron armor: A possible defense against cutaneous inflammation and cancer

Arbiser

Bonner

Ward

et al. 2018

Biochimica et Biophysica Acta (BBA) - General Subjects

View full text Add to dashboard Cite

show abstract

“…These results might be because these patients had many symptoms present on the skin surface, which lead them to be more concerned about their risk of skin cancer. A previous study on atopic eczema confirmed the increased risk of squamous cell carcinoma but not malignant melanoma among atopic dermatitis patients [10,11].…”

Section: Discussionmentioning

confidence: 73%

Attitudes about and practices for skin cancer prevention among patients with dermatological issues in Hanoi, Vietnam: a cross-sectional study

Nguyen

Tran

Nguyen

et al. 2020

Environ Health Prev Med

View full text Add to dashboard Cite

Background: Raising awareness and educating people regarding practices for skin cancer or melanoma prevention are critical in the context of the adversely increasing effects of global climate change. This study aimed to explore the knowledge, attitudes, and practices regarding skin cancer prevention and to determine the associated factors to knowledge, attitudes, and practices among dermatological patients in Vietnam. Methods: This cross-sectional study included 590 dermatological patients between 18 and 82 years of age, who received an examination or treatment from the National Hospital of Dermatology in Hanoi, Vietnam, from September to December 2018. The respondents' attitudes on skin cancer and cancer prevention were assessed via face-to-face interviews with a structured questionnaire conducted by trained interviewers. Results: Of the 590 respondents, the majority of people had correct responses to the question regarding skin cancer knowledge. Among the total participants, 39.8% thought that they were at risk of skin cancer, and 13.8% believed their occupation increased their skin cancer risk. The majority of respondents used hats (94.9%) and sunscreen skin coats (89.5%) and went into the shade (86.3%) when exposed to the sun. Women were less likely to be aware of their skin cancer risk but were more likely to practice prevention behaviors. Conclusion: Our results show that dermatological patients have acceptable knowledge towards skin cancer prevention, but still need to change their behavior to prevent the risk of skin cancer. This study highlights the importance of education to raise awareness regarding skin cancer in order to promote practice prevention strategies for skin cancer in Vietnam.

show abstract

Association between atopic dermatitis and squamous cell carcinoma: a case–control study

Abstract: Our findings support an increased risk of SCC development in the setting of AD.

Cited by 20 publications

References 22 publications

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

Selenium unmasks protective iron armor: A possible defense against cutaneous inflammation and cancer

Attitudes about and practices for skin cancer prevention among patients with dermatological issues in Hanoi, Vietnam: a cross-sectional study

Contact Info

Product

Resources

About